Preparation of chitosan-coated hollow tin dioxide nanoparticles and their application in improving the oral bioavailability of febuxostat

Preparation of chitosan-coated hollow tin dioxide nanoparticles and their application in improving the oral bioavailability of febuxostat

The aim of this study was to design a chitosan-coated hollow tin dioxide nanosphere (CS-HSn) for loading febuxostat (FEB) using an adsorption method to obtain a sustained-release system (CS-HSn-FEB) to improve the oral bioavailability of FEB. The morphological characteristics of hollow tin dioxide n...

Full description

Bibliographic Details
Main Authors:	Junpeng Sun, Jiaqun Du, Xiaobang Liu, Jinyu An, Yingqiao Li, Yanan Yu, Minghui Li, Li Zheng, Chao Wu, Lili Hu
Format:	Article
Language:	English
Published:	Elsevier 2023-12-01
Series:	International Journal of Pharmaceutics: X
Subjects:	Febuxostat Tin dioxide Chitosan Saturation solubility Dissolution rate Oral bioavailability
Online Access:	http://www.sciencedirect.com/science/article/pii/S2590156723000439

Similar Items

Solubility and Thermodynamic Data of Febuxostat in Various Mono Solvents at Different Temperatures
by: Nazrul Haq, et al.
Published: (2022-06-01)

Quality-by-design based fabrication of febuxostat-loaded nanoemulsion: Statistical optimization, characterizations, permeability, and bioavailability studies
by: Vishal C. Gurumukhi, et al.
Published: (2023-04-01)

The Role of Functional Excipients in Solid Oral Dosage Forms to Overcome Poor Drug Dissolution and Bioavailability
by: Jannes van der Merwe, et al.
Published: (2020-04-01)

Development and evaluation of febuxostat solid dispersion through screening method
by: Jeong Sun Sohn, et al.
Published: (2023-09-01)

Development of a tin oxide carrier with mesoporous structure for improving the dissolution rate and oral relative bioavailability of fenofibrate
by: Bai A, et al.
Published: (2018-07-01)

Evaluation of Pharmacokinetic Feasibility of Febuxostat/L-pyroglutamic Acid Cocrystals in Rats and Mice
by: Jeong-Eun Yu, et al.
Published: (2023-08-01)

<i>In-vitro</i> dissolution profiles comparison for various drugs with active ingredient Febuxostat commercially available on the Russian market
by: S. V. Denkina, et al.
Published: (2024-01-01)

A rare case of thrombocytopenia secondary to taking febuxostat
by: Isabella Di Zio, et al.
Published: (2024-04-01)

Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics
by: Dixit V. Bhalani, et al.
Published: (2022-08-01)

Celebrating Versatility: Febuxostat’s Multifaceted Therapeutic Application
by: Krasimir Iliev Kraev, et al.
Published: (2023-11-01)

Preparation and Characterization of Febuxostat as Nanosuspension
by: Zahraa Salim Alwan, et al.
Published: (2025-02-01)

Investigating the Potential of Transmucosal Delivery of Febuxostat from Oral Lyophilized Tablets Loaded with a Self-Nanoemulsifying Delivery System
by: Yasir A. Al-Amodi, et al.
Published: (2020-06-01)

Febuxostat in the therapy of gout: from theory to practice
by: E. V. Ilyinykh, et al.
Published: (2018-01-01)

Pharmaceutical Dispersion Techniques for Dissolution and Bioavailability Enhancement of Poorly Water-Soluble Drugs
by: Xingwang Zhang, et al.
Published: (2018-06-01)

Improvement of solubility, dissolution, and bioavailability of phenytoin intercalated in Mg-Al layered double hydroxide
by: Rehab Anwar Bakr, et al.
Published: (2024-08-01)

Preparation of <i>trans</i>-Crocetin with High Solubility, Stability, and Oral Bioavailability by Incorporation into Three Types of Cyclodextrins
by: Nan Liu, et al.
Published: (2023-12-01)

Cardiovascular safety of febuxostat. Analysis of the CARES study
by: M. S. Eliseev
Published: (2018-12-01)

Enhanced Dissolution and Oral Bioavailability of Piroxicam Formulations: Modulating Effect of Phospholipids
by: Muhammad D. Hussain, et al.
Published: (2010-10-01)

Effect of Deep Eutectic System (DES) on Oral Bioavailability of Celecoxib: In Silico, In Vitro, and In Vivo Study
by: Soumalya Chakraborty, et al.
Published: (2023-09-01)

Structural Characterization of Febuxostat/l-Pyroglutamic Acid Cocrystal Using Solid-State 13C-NMR and Investigational Study of Its Water Solubility
by: Ji-Hun An, et al.
Published: (2017-12-01)

Febuxostat-Minoxidil Salt Solvates: Crystal Structures, Characterization, Interconversion and Solubility Performance
by: Li-Yang Li, et al.
Published: (2018-02-01)

Comparison of Xanthine Oxidase Inhibitory Effect of Swertia chirayita and Febuxostat in Vitro
by: Qura-Tul-Ain, et al.
Published: (2021-04-01)

Response to febuxostat according to clinical subtypes of hyperuricemia: a prospective cohort study in primary gout
by: Han Qi, et al.
Published: (2023-12-01)

A retrospective observational study of the appropriate starting dose of febuxostat in patients with gout
by: Joondon Lee, et al.
Published: (2023-05-01)

Nefroprotective properties of febuxostat in chronic renal failure
by: Z. V. Babenko
Published: (2019-09-01)

Formulation and Evaluation of a Self-Microemulsifying Drug Delivery System of Raloxifene with Improved Solubility and Oral Bioavailability
by: Muhammad Mohsin Ansari, et al.
Published: (2023-08-01)

Impact of crystal polymorphism of rifaximin on dissolution behavior
by: Imen Toukabri, et al.
Published: (2024-03-01)

The place of febuxostat in the treatment of gout
by: A. M. Novikova, et al.
Published: (2020-09-01)

Anti-hyperuricemic Evaluation of Swertia-chirayita and Febuxostat on Potassium Oxonate Induced Hyperuricemic Animal Model
by: Qura-Tul-Ain, et al.
Published: (2024-04-01)

Anti-hyperuricemic Evaluation of Swertia-chirayita and Febuxostat on Potassium Oxonate Induced Hyperuricemic Animal Model
by: Qura-Tul-Ain, et al.
Published: (2024-04-01)

Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial
by: Dewi C, et al.
Published: (2023-09-01)

Comment on “A Randomized, Double-Blind, Non-inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects with or Without Gout”
by: Kevin D. B. van Leeuwen, et al.
Published: (2019-12-01)

The use of febuxostat in comorbid patients with gout in real clinical practice: own data
by: E. V. Zonova, et al.
Published: (2022-06-01)

Self-emulsifying micelles as a drug nanocarrier system for itraconazole oral bioavailability enhancement; in vitro and in vivo assessment
by: Nayyer Islam, et al.
Published: (2023-12-01)

Experience with febuxostat in a patient with severe disabling gout
by: M. S. Eliseev, et al.
Published: (2017-09-01)

FEBUXOSTAT FOR TREATMENT OF CHRONIC HYPERURICEMIA IN GOUT PATIENTS
by: M. S. Petrova, et al.
Published: (2017-11-01)

Effects of Febuxostat Therapy on Circulating Adipokine Profiles in Patients with Overweight or Obesity and Asymptomatic Hyperuricemia: A Randomized Controlled Study
by: Meijuan Dong, et al.
Published: (2024-08-01)

Optimized solubility and bioavailability of genistein based on cocrystal engineering
by: Zhipeng Wang, et al.
Published: (2023-09-01)

Formulation Development of Fast Dissolving Microneedles Loaded with Cubosomes of Febuxostat: In Vitro and In Vivo Evaluation
by: Brijesh Patel, et al.
Published: (2023-01-01)

Febuxostat Mitigates Genotoxicity Induced by Ionizing Radiation in Human Normal Lymphocytes
by: Shiva Asemi, et al.
Published: (2019-03-01)